CN111295380A - 一种高活性csf1r抑制剂化合物 - Google Patents

一种高活性csf1r抑制剂化合物 Download PDF

Info

Publication number
CN111295380A
CN111295380A CN201980005226.1A CN201980005226A CN111295380A CN 111295380 A CN111295380 A CN 111295380A CN 201980005226 A CN201980005226 A CN 201980005226A CN 111295380 A CN111295380 A CN 111295380A
Authority
CN
China
Prior art keywords
cancer
compound
stereoisomers
cycloalkyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980005226.1A
Other languages
English (en)
Other versions
CN111295380B (zh
Inventor
刘世峰
俞智勇
庞伟
王骥
陈鹏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xiamen Baotai Biotechnology Co ltd
Original Assignee
Hangzhou Arnold Biomedical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Arnold Biomedical Technology Co ltd filed Critical Hangzhou Arnold Biomedical Technology Co ltd
Priority to CN202010437241.8A priority Critical patent/CN111484442B/zh
Priority to CN202010438087.6A priority patent/CN111548343B/zh
Priority to CN202010437243.7A priority patent/CN111518016B/zh
Publication of CN111295380A publication Critical patent/CN111295380A/zh
Application granted granted Critical
Publication of CN111295380B publication Critical patent/CN111295380B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/54—Spiro-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

本发明涉及CSF1R抑制剂，具体涉及一种高活性的CSF1R抑制剂化合物，所述化合物具有式I结构，本发明的化合物对CSF1R具有高的抑制活性。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN201980005226.1A 2018-06-01 2019-05-24 一种高活性csf1r抑制剂化合物 Active CN111295380B (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202010437241.8A CN111484442B (zh) 2018-06-01 2019-05-24 一种具有抗肿瘤活性的csf1r抑制剂中间体的制备方法
CN202010438087.6A CN111548343B (zh) 2018-06-01 2019-05-24 一种高活性csf1r抑制剂化合物的制备方法
CN202010437243.7A CN111518016B (zh) 2018-06-01 2019-05-24 一种csf1r抑制剂中间体及其制备方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810559228 2018-06-01
CN2018105592282 2018-06-01
PCT/CN2019/088221 WO2019228252A1 (zh) 2018-06-01 2019-05-24 一种高活性csf1r抑制剂化合物

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CN202010438087.6A Division CN111548343B (zh) 2018-06-01 2019-05-24 一种高活性csf1r抑制剂化合物的制备方法
CN202010437243.7A Division CN111518016B (zh) 2018-06-01 2019-05-24 一种csf1r抑制剂中间体及其制备方法
CN202010437241.8A Division CN111484442B (zh) 2018-06-01 2019-05-24 一种具有抗肿瘤活性的csf1r抑制剂中间体的制备方法

Publications (2)

Publication Number Publication Date
CN111295380A true CN111295380A (zh) 2020-06-16
CN111295380B CN111295380B (zh) 2020-11-20

Family

ID=68697839

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202010437243.7A Active CN111518016B (zh) 2018-06-01 2019-05-24 一种csf1r抑制剂中间体及其制备方法
CN201980005226.1A Active CN111295380B (zh) 2018-06-01 2019-05-24 一种高活性csf1r抑制剂化合物
CN202010438087.6A Active CN111548343B (zh) 2018-06-01 2019-05-24 一种高活性csf1r抑制剂化合物的制备方法
CN202010437241.8A Active CN111484442B (zh) 2018-06-01 2019-05-24 一种具有抗肿瘤活性的csf1r抑制剂中间体的制备方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202010437243.7A Active CN111518016B (zh) 2018-06-01 2019-05-24 一种csf1r抑制剂中间体及其制备方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202010438087.6A Active CN111548343B (zh) 2018-06-01 2019-05-24 一种高活性csf1r抑制剂化合物的制备方法
CN202010437241.8A Active CN111484442B (zh) 2018-06-01 2019-05-24 一种具有抗肿瘤活性的csf1r抑制剂中间体的制备方法

Country Status (5)

Country Link
US (1) US11591328B2 (zh)
EP (1) EP3744718A4 (zh)
JP (1) JP7090958B2 (zh)
CN (4) CN111518016B (zh)
WO (1) WO2019228252A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115137731A (zh) * 2022-05-19 2022-10-04 上海交通大学医学院附属新华医院 Flt3抑制剂及其药学上可接受的盐在制备治疗皮肤t细胞淋巴瘤药物中的应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019014021A (es) * 2017-05-24 2020-08-17 Abbisko Therapeutics Co Ltd Derivado de n-(azaarilo)ciclo lactam-1-carboxamida, metodo de preparacion del mismo y uso del mismo.
CN115385896A (zh) * 2021-05-24 2022-11-25 上海和誉生物医药科技有限公司 一种csf-1r抑制剂中间体或其酸式盐的制备方法
CN116178281B (zh) * 2023-04-27 2023-07-21 中国药科大学 一种双功能免疫抑制剂及其制备方法和应用

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006116713A1 (en) * 2005-04-27 2006-11-02 Amgen Inc. Substituted amide derivatives as protein kinase inhibitors
CN103539780A (zh) * 2012-07-16 2014-01-29 广东东阳光药业有限公司 取代的吡唑酮化合物及其使用方法和用途
WO2014022117A1 (en) * 2012-07-28 2014-02-06 Calitor Sciences, Llc Substituted pyrazolone compounds and methods of use
WO2014145015A2 (en) * 2013-03-15 2014-09-18 Deciphera Pharmaceuticals, Llc Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities
US20150037280A1 (en) * 2012-07-28 2015-02-05 Sunshine Lake Pharma Co., Ltd. Substituted pyrazolone compounds and methods of use
CN104974162A (zh) * 2014-04-09 2015-10-14 广东东阳光药业有限公司 双环吡唑酮化合物及其使用方法和用途
WO2015164161A1 (en) * 2014-04-22 2015-10-29 Calitor Sciences, Llc Bicylcic pyrazolone compounds and methods of use
WO2017176792A1 (en) * 2016-04-04 2017-10-12 Massachusetts Institute Of Technology Methods of preventing or reducing a fibrotic response using csf 1r inhibitors
WO2018081254A1 (en) * 2016-10-26 2018-05-03 Cao Group, Inc. Cancer binding chromatic peptides that are targeted for disintegration by radiant energy
WO2018214867A1 (zh) * 2017-05-24 2018-11-29 上海和誉生物医药科技有限公司 N-(氮杂芳基)环内酰胺-1-甲酰胺衍生物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102066372B (zh) * 2009-08-24 2014-09-17 苏州爱斯鹏药物研发有限责任公司 含脲基的5，6元杂芳双环化合物作为激酶抑制剂
UY35834A (es) * 2013-11-14 2015-05-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon
BR112017000762A2 (pt) * 2014-07-15 2017-11-21 Gruenenthal Gmbh derivados de azaspiro(4.5)decano substituído.
CN106279138B (zh) * 2015-12-29 2019-03-01 广东东阳光药业有限公司 芳杂环类衍生物及其在药物中的应用

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006116713A1 (en) * 2005-04-27 2006-11-02 Amgen Inc. Substituted amide derivatives as protein kinase inhibitors
CN103539780A (zh) * 2012-07-16 2014-01-29 广东东阳光药业有限公司 取代的吡唑酮化合物及其使用方法和用途
WO2014022117A1 (en) * 2012-07-28 2014-02-06 Calitor Sciences, Llc Substituted pyrazolone compounds and methods of use
US20150037280A1 (en) * 2012-07-28 2015-02-05 Sunshine Lake Pharma Co., Ltd. Substituted pyrazolone compounds and methods of use
WO2014145015A2 (en) * 2013-03-15 2014-09-18 Deciphera Pharmaceuticals, Llc Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities
US20140315917A1 (en) * 2013-03-15 2014-10-23 Deciphera Pharmaceuticals, Llc Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities
CN104974162A (zh) * 2014-04-09 2015-10-14 广东东阳光药业有限公司 双环吡唑酮化合物及其使用方法和用途
WO2015164161A1 (en) * 2014-04-22 2015-10-29 Calitor Sciences, Llc Bicylcic pyrazolone compounds and methods of use
WO2017176792A1 (en) * 2016-04-04 2017-10-12 Massachusetts Institute Of Technology Methods of preventing or reducing a fibrotic response using csf 1r inhibitors
WO2018081254A1 (en) * 2016-10-26 2018-05-03 Cao Group, Inc. Cancer binding chromatic peptides that are targeted for disintegration by radiant energy
WO2018214867A1 (zh) * 2017-05-24 2018-11-29 上海和誉生物医药科技有限公司 N-(氮杂芳基)环内酰胺-1-甲酰胺衍生物及其制备方法和应用
CN110573500A (zh) * 2017-05-24 2019-12-13 上海和誉生物医药科技有限公司 N-(氮杂芳基)环内酰胺-1-甲酰胺衍生物及其制备方法和应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FLORENT PEYRAUD ET AL.: "CSF-1R Inhibitor Development: Current Clinical Status", 《CURR ONCOL REP》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115137731A (zh) * 2022-05-19 2022-10-04 上海交通大学医学院附属新华医院 Flt3抑制剂及其药学上可接受的盐在制备治疗皮肤t细胞淋巴瘤药物中的应用
CN115137731B (zh) * 2022-05-19 2023-11-21 上海交通大学医学院附属新华医院 Flt3抑制剂及其药学上可接受的盐在制备治疗皮肤t细胞淋巴瘤药物中的应用

Also Published As

Publication number Publication date
EP3744718A1 (en) 2020-12-02
US20200399265A1 (en) 2020-12-24
WO2019228252A1 (zh) 2019-12-05
CN111295380B (zh) 2020-11-20
CN111484442B (zh) 2021-11-09
CN111484442A (zh) 2020-08-04
JP7090958B2 (ja) 2022-06-27
CN111518016A (zh) 2020-08-11
CN111548343A (zh) 2020-08-18
EP3744718A4 (en) 2021-11-17
JP2021520418A (ja) 2021-08-19
CN111518016B (zh) 2022-02-25
US11591328B2 (en) 2023-02-28
CN111548343B (zh) 2021-06-01

Similar Documents

Publication Publication Date Title
CN111295380B (zh) 一种高活性csf1r抑制剂化合物
CN111989313A (zh) A2a和/或a2b受体拮抗剂
CN111406050B (zh) 吲哚胺2,3-双加氧酶抑制剂及其用途
CN112028891B (zh) 腺苷受体拮抗剂
US20230399327A1 (en) High activity hpk1 kinase inhibitor
JP7281834B2 (ja) Ｐｄ－ｌ１拮抗薬化合物
CN115066423A (zh) Pd-l1拮抗剂化合物
TWI768781B (zh) 轉化生長因子－β受體抑制劑
CN111825698B (zh) 腺苷受体拮抗剂
CN111440148B (zh) 一种腺苷受体拮抗剂的制备方法
LU505117B1 (en) A pan-KRAS inhibitor compound
WO2022199561A1 (zh) Hpk1激酶抑制剂化合物
CN118047799A (zh) 一种pan-KRAS抑制剂化合物
WO2022214008A1 (zh) 高活性hpk1激酶抑制剂
CN117396482A (zh) 一种Wnt通路抑制剂化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: 310000 Building 8, No. 1008, Longxiang street, Cangqian street, Yuhang District, Hangzhou City, Zhejiang Province

Applicant after: Hangzhou Arnold Biomedical Technology Co.,Ltd.

Address before: 310018 21 / F, building 2, No.452, No.6 street, Hangzhou Economic and Technological Development Zone, Hangzhou, Zhejiang Province

Applicant before: Hangzhou Arnold Biomedical Technology Co.,Ltd.

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20211126

Address after: 361000 floor 3-5, No. 188, Pingcheng South Road, Haicang street, Haicang District, Xiamen City, Fujian Province

Patentee after: Xiamen Baotai Biotechnology Co.,Ltd.

Address before: 310000 Building 8, No. 1008, Longxiang street, Cangqian street, Yuhang District, Hangzhou City, Zhejiang Province

Patentee before: Hangzhou Arnold Biomedical Technology Co.,Ltd.